Advisory Services Network LLC Sells 2,667 Shares of Danaher Co. (NYSE:DHR)

Advisory Services Network LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,083 shares of the conglomerate’s stock after selling 2,667 shares during the quarter. Advisory Services Network LLC’s holdings in Danaher were worth $4,183,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. First Trust Bank Ltd. bought a new position in shares of Danaher during the fourth quarter worth $1,134,000. Team Hewins LLC acquired a new position in Danaher in the 4th quarter valued at about $1,848,000. Cypress Asset Management Inc. TX bought a new stake in Danaher in the 4th quarter valued at about $3,833,000. Hohimer Wealth Management LLC boosted its holdings in Danaher by 1.6% in the 4th quarter. Hohimer Wealth Management LLC now owns 11,654 shares of the conglomerate’s stock valued at $2,696,000 after purchasing an additional 183 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in Danaher by 20.3% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 57,659 shares of the conglomerate’s stock valued at $13,339,000 after purchasing an additional 9,744 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

DHR stock traded up $1.38 during midday trading on Friday, reaching $262.78. The company had a trading volume of 2,089,037 shares, compared to its average volume of 2,351,652. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $268.98. The company has a market capitalization of $194.64 billion, a P/E ratio of 44.54, a P/E/G ratio of 4.02 and a beta of 0.83. The firm has a 50-day moving average price of $249.96 and a 200-day moving average price of $238.95.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the previous year, the company earned $2.36 EPS. The business’s quarterly revenue was down 2.6% compared to the same quarter last year. On average, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity

In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 172,540 shares of company stock valued at $43,523,481. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of recent analyst reports. Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Raymond James increased their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. TD Cowen increased their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, Barclays raised their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.